United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down Posted byZacks Equity Research February 25, 2022 Leave a comment on United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.